A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group-Reference-Cited by-同舟云学术

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group

Published:2018-10-30 Issue:2 Volume:66 Page:e27524
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Isakoff Michael S.¹^ORCID,Goldsby Robert²,Villaluna Doojduen³,Krailo Mark D.³⁴,Hingorani Pooja⁵,Collier Anderson⁶,Morris Carol D.⁷^ORCID,Kolb E. Anders⁸,Doski John J.⁹,Womer Richard B.¹⁰,Gorlick Richard¹¹,Janeway Katherine A.¹²^ORCID

Affiliation:

1. Center for Cancer and Blood Disorders; Connecticut Children's Medical Center; Hartford Connecticut

2. Division of Pediatric Hematology/Oncology; University of California San Francisco; Benioff Children's Hospital; San Francisco California

3. Children's Oncology Group; Monrovia California

4. Department of Preventive Medicine; Keck School of Medicine; University of Southern California; Los Angeles California

5. Center for Cancer and Blood Disorders; Phoenix Children's Hospital; Phoenix Arizona

6. Hematology/Oncology; University of Mississippi Medical Center; Jackson Mississippi

7. Division of Orthopaedic Oncology; John Hopkins Medicine; Baltimore Maryland

8. Alfred I DuPont Hospital for Children; Wilmington Delaware

9. Department of Surgery/Pediatric Surgery Division; University of Texas Health Science Center; San Rosa Children's Hospital; San Antonio Texas

10. Division of Oncology; The Children's Hospital of Philadelphia; University of Pennsylvania; Philadelphia Pennsylvania

11. Division of Pediatrics; The University of Texas; MD Anderson Cancer Center; Baltimore Maryland

12. Department of Pediatric Oncology; Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Boston Massachusetts

Funder

Children's Oncology Group Chair's Grant

NCTN Operations Center Grant

NCTN Statistics

Reid R. Sacco Adolescent and Young Adult Cancer Alliance

St. Baldrick's Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27524/fullpdf

Reference29 articles.

1. Outcomes for children and adolescents with cancer: challenges for the twenty-first century;Smith;J Clin Oncol,2010

2. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS);Kempf-Bielack;J Clin Oncol,2005

3. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide;Bacci;Ann Oncol,2003

4. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis;Marina;Cancer,1992

5. Osteogenic sarcoma with clinically detectable metastasis at initial presentation;Meyers;J Clin Oncol,1993

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement;Clinical Cancer Research;2024-06-13

2. Dynamic network curvature analysis of gene expression reveals novel potential therapeutic targets in sarcoma;Scientific Reports;2024-01-04

3. A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?;Cancer Treatment Reviews;2023-11

4. A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages;Cancers;2023-09-19

5. Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine;Biomolecules;2023-09-07